Companies: 10,795·Total market cap: $144.5T
Alps Group Inc

Alps Group Inc

ALPSNASDAQHealthcare● Active
$0.72
+$0.01(+1.06%)
Market Cap$119392237
P/E Ratio
52W High$2.9
52W Low$0.562
Overview

Alps Group Inc(ALPS)股票概览

关键指标与盈利、估值、营收、股息等标签页深链。

FMP · ALPS · 截至 Jun 9, 2026

关键指标

EPS (TTM)$-14.79alps eps ttm · alps earnings per shareEarnings history
PE Ratio (TTM)alps pe ratio ttm · alps price to earningsPE Ratio deep dive
Revenue (TTM)$3.4Malps revenue ttm · alps annual revenueFull revenue history
Dividend Yield不分红does alps pay dividends · alps dividend yieldDividend history
Shares Outstanding4.6Malps shares outstanding · alps floatShares outstanding history
Next EarningsTBAalps earnings date · alps next earningsEarnings history

财务快照

完整财报
FY 2025Revenue$3.4M▲ +0.00% YoY
202420252025
alps group inc revenue · alps revenue 2025
FY 2025Net Income-$67.6M▼ 2588.33% YoY
202420252025
alps group inc net income · alps profit 2025
FY 2025EPS$-14.64▼ 2052.94% YoY
202420252025
alps eps · alps group inc earnings per share 2025
TTM:Revenue: $3.4MNet Income: -$67.6MEPS: $-14.79View income statement →

股票表现

完整历史
1D+1.06%
1W-1.99%
1M-12.62%
3M-18.56%
YTD-17.47%
1Y-94.03%
5Y-94.03%

关于 Alps Group Inc

CEOSeng Kong Tham
IPO DateOct 31, 2025
Employees2
CountryMY

Alps Group Inc operates as a comprehensive biotechnology firm, delivering a wide array of services ranging from groundbreaking research and development to direct medical care and health optimization …

what is alps group inc · alps stock overview · alps group inc company profile · who is alps group inc ceo · alps NASDAQ · alps group inc headquarters · alps group inc business segments

关于股票概览与关键数据

Alps Group Inc(ALPS)是 Biotechnology 行业的 Healthcare 类公司,于 Oct 31, 2025 在 NASDAQ 上市。截至最近交易日,ALPS 股价为 $0.72,市值约为 $119.4M。过去12个月累计回报 -94.03%,年初至今回报 -17.47%。

2025 财年 Alps Group Inc 营收 $3.4M。完整财务数据(营收历史、盈利、资产负债表)请使用上方标签页。

常见问题

截至最近一个交易日,Alps Group Inc(ALPS)股价为 $0.72,在 NASDAQ 上市,52周区间为 $0.56 – $2.90。

ALPS 最新股价ALPS quote todaylive ticker 实时行情
数据来源:Financial Modeling Prep最后更新:Jun 9, 2026本内容不构成投资建议